Cardiology

View All

upcoming-cardiovascular-drugs
Major Drugs Decisions for Cardiovascular Diseases to Watch Through 2022

The discovery of new classes of highly effective drug therapy for prevalent kinds of cardiovascular diseases has witnessed spectacular success in recent decades. The widespread use of these cardiovascular drugs, combined with smoking cessation and nonpharmacological therapy, is thought to be responsible for decreas...

Find More

key-cardiovascular-disease-risk-factors
Rising Global Prevalence of Cardiovascular Diseases And Top Players In Cardiology

Cardiovascular Diseases (CVDs), primarily constituting heart failure, ischemic heart disease, stroke, are considered as leading global cause of mortality and a major contributor to disability. Over the last 30 years, deaths and disabilities from Cardiovascular Disease have been steadily rising across the globe. Car...

Find More

Neprilysin Inhibitor for Cardiovascular Diseases

According to National Society of Health, approximately 26 million patients are suffering from heart failure worldwide, with the increased economic burden of USD 30.7 billion each year. The advent of a novel class of drugs, i.e., the angiotensin receptor-neprilysin inhibitor, gives hope to the patients. Neprilysin is...

Find More